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Open access under CC BY-NC-ND license.How does signalling via PI3K–PKB (AKT)–mTORC1–
p70S6K and ERK–p90RSK mediate wide-ranging physio-
logical responses to insulin? Quantitative proteomics
and biochemical experiments are revealing that these
signalling pathways induce the phosphorylation of large
and overlapping sets of proteins, which are then
captured by phosphoprotein-binding proteins named
14-3-3 s. The 14-3-3 s are dimers that dock onto dual-
phosphorylated sites in a configuration with special
signalling and mechanical properties. They interact with
the Rab GTPase-activating proteins AS160 and TBC1D1
to regulate glucose uptake into target tissues in re-
sponse to insulin and energy stress. Dynamic patterns
in the 14-3-3-binding phosphoproteome are providing
new insights into how insulin triggers coherent shifts in
metabolism that are integrated with other cellular re-
sponse systems.
Established and emerging actions of insulin
Insulin is best known for suppressing blood glucose levels
by driving glucose from the bloodstream into muscle and
liver glycogen and into fat in adipose tissue, and for
inhibiting glucose production from the liver. However,
these actions are only part of an orchestrated shift in global
metabolism induced by insulin action. Nutrients and ions
surge into our bloodstream after a meal, and insulin directs
the assimilation of glucose, metal ions, amino acids and
lipids according to the demands of specialized tissues in
ways that ensure whole-body homeostasis, electrochemical
balance of ions across membranes, and stoichiometric
balance in fluxes through metabolic pathways.
Although the main targets for insulin-regulated glucose
homeostasis are muscle, fat and liver, insulin also prepares
other organs in their response to food. For example, it was
recently discovered that insulin induces cytoskeletal remo-
delling in kidney glomerular podocytes [1] and thus readies
the kidney for increased urine filtration following a meal.
Insulin influences vascular endothelium in ways that may
affect tissue blood flow, and regulates fuel use and cell
survival in the heart [2–5]. Insulin signalling to the hypo-
thalamus, pituitary, bone, pancreas and reproductive sys-
tems is also being recognised as critical to the whole-body
distribution of resources [6–9].Corresponding author: MacKintosh, C. (c.mackintosh@dundee.ac.uk).
1043-2760  2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.tem.2011.07.005The discovery that insulin has more widespread influ-
ences than was previously realised implies that complica-
tions of diabetes such as neuropathies, nephropathy, bone
disorders and heart disease might not be solely attribut-
able to hyperglycaemia, but could be due in part to deregu-
lated insulin action in the damaged tissues [10]. In any
case, an understanding of how insulin exerts its diverse
effects on different tissues is of enormous practical signifi-
cance given the growing worldwide burden of insulin re-
sistance and type 2 diabetes.
The immediate effects of insulin binding to its cognate
tyrosine kinase receptor are relatively well understood.
Phosphatidyinositol 3-kinase (PI3K)–protein kinase B
(PKB, also known as AKT)– mammalian target of rapa-
mycin complex 1 (mTORC1)–p70 ribosomal S6 kinase
(p70S6K) signalling is activated, and in some cell types
insulin also activates the Ras–Raf– extracellular signal-
regulated kinase (ERK)–p90 ribosomal S6 kinase
(p90RSK) pathway [11,12]. However, too few downstream
targets are known to explain how these core signalling
pathways stimulate diverse physiological responses to
insulin. Here, we review the roles of a family of phospho-
protein-binding proteins named 14-3-3 s in mediating in-
sulin responses. We outline how 14-3-3 proteins work and
focus on contributions of 14-3-3 s to key regulatory steps in
insulin-regulated glucose homeostasis. Recent develop-
ments in 14-3-3 affinity capture and proteomics technolo-
gies are also highlighted, which show promise as a way to
identify new intracellular targets and help to explain the
wider actions of insulin.
14-3-3 dimers dock onto specific pairs of
phosphorylated sites
The 14-3-3 s dock onto and regulate hundreds of phospho-
proteins inside eukaryotic cells, including proteins that
are deregulated in diabetes, cancer and neurological dis-
orders (Figure 1). Mammals have seven 14-3-3 genes
(gamma, epsilon, beta, zeta, sigma, theta, tau), and their
peculiar name refers to the discovery of the protein iso-
forms as a cluster of spots in position 14-3-3 on an early
two-dimensional starch gel separation of bovine brain
extract (Box 1) [13]. The numbers 14-3-3 have no function-
al significance; perhaps a more meaningful number for
these proteins is ‘two’, for they are dimers that bind two
phosphorylated residues. Often a 14-3-3 dimer docks onto
a pair of tandem phosphorylated sites on a target protein, Trends in Endocrinology and Metabolism, November 2011, Vol. 22, No. 11 429
ITB2
Metabolic 
MEFV 
GP1BA IGF1R
TY3H
IRS1
Tumorigenesis Psychiatric/behaviour
TPH2 TAU
P53
CHK1
PRLR
MDM2
CTNB1
AKP13
BRAF
ABL1
GLI2
LRRK2 ACHA4
SLIK1COF1
CDN1B
Cardiovascular 
TRENDS in Endocrinology & Metabolism 
Figure 1. The current 14-3-3 diseasome encompasses tumourigenesis, cardiovascular, metabolic and neurological disorders. Some 480 human disease gene sets described
in the Genetic Association Database were recently mapped to indicate the degree of gene sharing among diseases [68]. We extracted from this disease map the gold
standard proteins with defined 14-3-3-binding phosphorylation sites [15,69]. The 14-3-3 binders map predominantly in four disease classes: tumourigenesis (11 proteins:
P53, BRAF, MDM2, CDN1B, AKP13, IRS1, PRLR, CTNB1, CHK1, ABL1, GLI2), cardiovascular (6 proteins: GP1BA, TY3H, ITB2, MEFV, IRS1, CDN1B), metabolic (5 proteins:
IRS1, GP1BA, TY3H, IGF1R, MEFV) and psychiatric or behaviour (11 proteins: TAU, IGF1R, GP1BA, P53, LRRK2, TY3H, ACHA4, MEFV, COF1, SLIK1, TPH2). The protein
overlap between these classes is illustrated here by Visant graphing (http://visant.bu.edu). This map is just a starting point, with indications that the concentration of 14-3-3-
binding proteins in the tumourigenesis, cardiovascular, metabolic and neurological disease classes will increase. For example, AS160 and TBC1D1, mutations of which are
found in subtypes of diabetes and obesity, respectively [56,61,62], were not in the Genetic Association Database when the disease map was prepared [68]. Moreover, further
proteins linked to these four disease classes are among those that exhibit affinity for 14-3-3 s in high-throughput proteomics studies; these await biochemical studies to
define the specificity of their interactions with 14-3-3 [23,24,26,27].
Review Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11which is a configuration that confers interesting signalling
and mechanical properties [14–16].
The act of docking onto two phosphorylated residues
turns a 14-3-3 dimer into a type of biochemical microcon-
troller called a logic gate (Figure 2a). Logic gates are
fundamental components of digital electronic circuits,
where they perform OR and AND operations on two or
more inputs to produce a single output. The concept is
useful because an increasing number of proteins are being
identified in which two tandem phosphorylated 14-3-3-
binding sites can be phosphorylated by distinct protein
kinases [15]. One is the BCL-XL/BCL2-associated death430promoter (BAD) for which the 14-3-3 has been proposed as
an OR gate because phosphorylation of either site is suffi-
cient to recruit 14-3-3, which in turn promotes cell survival
by preventing BAD binding to the anti-apoptotic BCL-XL
[17]. The 14-3-3 would be an AND gate if both sites must be
phosphorylated, and by different kinases, for a 14-3-3 to
bind and exert its action. Such devices would filter out
signalling noise because only the correct combination of
inputs would trigger an output. In biological systems, the
digital logic is likely to be more ‘fuzzy’ than in electronic
circuits, because the phosphorylation and binding kinetics
often differ for the two 14-3-3 interaction sites. Later in this
PKinase 2 Kinase 1
P
(a)
Mechanical action
(c)
(b)
‘AND’ ‘OR’
Hypothetical
clip function PP
Mask
PP
Lever
PP
Adapter
P P
Proliferative
stimuli 
Ca2+
Insulin & growth factors
Various stimuli
in different cell types 
PMA,
platelet activators,
etc 
Energy
deprivation 
PKA
Pims
PKC
AMPK
Akt/PKB
TRENDS in Endocrinology & Metabolism 
Figure 2. 14-3-3 dimers are logic gates and mechanical devices that dock onto two CAMK- and AGC-phosphorylated sites. (a) Analogy between a 14-3-3 dimer and digital
logic gates. Digital AND and OR gates, which integrate two inputs into a single output, are depicted on the right. The left-hand side shows how the act of docking onto two
sites, which may be phosphorylated by different kinases, turns the 14-3-3 dimer into a digital logic gate whose output is a mechanical action. (b) The 14-3-3 s are dimeric
regulatory proteins that dock onto two phosphorylated residues, which are usually on the same target protein. Mechanically, this means that 14-3-3 can act as levers to force
a conformational change in a target, can mask a functional domain within the central groove, and can potentially clip back flanking regions to present a functional domain
for external interactions. When the two phosphorylated 14-3-3-binding sites are on different proteins, the 14-3-3 dimer would be an adapter that stabilises the interaction
between the two targets. 14-3-3 s are remarkable for having hundreds of phosphoprotein partners. (c) Phosphorylated 14-3-3-binding sites are created by CAMK and AGC
kinases. The frequency plot at the bottom was generated by aligning the sequences around more than 200 14-3-3-binding sites, centred on the phosphorylated 14-3-3-
binding residue, which can be serine or threonine [15]. Most 14-3-3-binding sites have arginine somewhere in the -3 to -5 positions relative to the phosphorylated site, and
just under half have a proline at +2. Such sites are generally phosphorylated by basophilic kinases in the AGC and CAMK sections of the human kinome, including central
mediators of insulin and nutrient signaling.
Review Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11review we consider cases for which fuzzy 14-3-3 AND gates
might integrate insulin signalling with other cellular
signals.
In electronic circuits, the output of a logic gate is an
electrical impulse. In intracellular circuits, a 14-3-3 dock-
ing event triggers a mechanical action [18]. The two phos-
phorylated 14-3-3-binding sites on target proteins are
generally located within disordered regions and/or strad-
dle a functional domain [15]. Their positions can give clues
about how 14-3-3 dimers modulate the conformations and
interactions of their targets (Figure 2b). 14-3-3 s can act as
levers, whereby one site acts as a fulcrum for the 14-3-3
dimer to exert a force on the other site, which causes aconformational change in the target. For example, a 14-3-3
dimer alters the conformations of phosphorylated tyrosine
hydroxylase and the GTPase-activating protein RGS3 to
activate these enzymes [19,20]. In other cases, 14-3-3
dimers mask a subcellular targeting sequence or a func-
tional domain. For example 14-3-3 binds to PKB-phosphor-
ylated FOXO4, which shields the DNA binding interface
of this transcription factor and also interferes with its
nuclear localization [21]. In this way, 14-3-3 inhibits tran-
scriptional activation when FOXO4 is phosphorylated in
response to insulin and other stimuli. In principle, a 14-3-3
dimer could clip back flanking regions to better present a
functional domain for external interactions, but there are431
Box 1. 14-3-3 proteins
 14-3-3 s are phosphoprotein-binding proteins with many regula-
tory roles in all eukaryotes.
 Dimers of curved L-shaped monomers (30 kDa) form a central
groove that docks onto two phosphorylated sites on targets.
 AGC and CAMK kinases phosphorylate many of the known 14-3-3-
binding sites.
 The two phosphorylated docking sites must be spatially compa-
tible with fitting into either side of the central groove (35 A˚
across).
 Different eukaryotic lineages have evolved sets of 14-3-3 isoforms
(e.g. gamma, epsilon, beta, zeta, sigma, theta and tau in
mammals).
 All 14-3-3 isoforms share a similar mode of action, but may differ
in their ability to form hetero- and homodimers, in affinities for
different targets, in expression patterns and in their post-
translational regulation.
Review Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11no compelling examples of this. A 14-3-3 dimer may also act
as an adapter linking two phosphorylated proteins, and a
convincing case of this mode of action is the stabilisation
and activation of the hexomeric plasma membrane proton
ATPase in plants by phosphorylation-dependent interac-
tions with three 14-3-3 dimers [22].
AGC and CAMK protein kinases phosphorylate many
14-3-3-binding sites
14-3-3 s interact with many phosphoproteins [23] and pro-
vide a common mechanism for linking signalling pathways
to cell metabolism, growth, proliferation and morphology.
With so many targets and over 500 human protein kinases,
it seems daunting to sort out which kinase phosphorylates
which 14-3-3-binding sites and when. Fortunately, the task
is simplified because much of the kinome can be disregarded:
14-3-3 s do not bind to phosphorylated tyrosines, nor gener-
ally to phosphorylated serines and threonines that are
followed by proline residues. This means that neither
tyrosine kinases nor proline-directed enzymes, such as
mitogen-activated protein (MAP) kinases and cyclin-depen-
dent protein kinases, create docking sites for 14-3-3 s. Mode
I RXX(pS/pT)XP and mode II RX(F/Y)X(pS)XP sequence
motifs showed optimal binding to 14-3-3 s in a screen of a
phosphopeptide library [16]. In a recent survey of defined
14-3-3-binding sites in mammalian proteins, mode I
RXX(pS/pT)XP motifs dominate, although the +2 proline
residue occurs in less than half (Figure 2c). Interestingly,
these 14-3-3-binding sequences overlap with the specifici-
ties of the protein kinase A/protein kinase G/protein kinase
C (AGC) group and Ca2+/calmodulin protein kinase (CAMK)
group of protein kinases [15], which exhibit individual pre-
ferences for phosphorylating motifs with basic residues in
the -3 to -5 positions relative to the phosphorylated residue.
These basophilic kinases include proviral integration of
MMLV (PIM) kinases, protein kinase C (PKC) isoforms,
the energy-sensing AMP-activated protein kinase (AMPK),
and the insulin-activated PKB, SGK, p70S6K and p90RSKs
(Figure 2c).
14-3-3 capture and release combined with differential
proteomics
There are many proteins whose binding to 14-3-3 s is
dynamically regulated by insulin, growth factors and432nutrients. Their identification is aided by recent develop-
ments in high-resolution mass spectrometry and quantita-
tive proteomics; thus, proteins within complex mixtures
can be identified and quantified, and their post-transla-
tional modification status can be analysed. For example,
14-3-3 affinity capture can be used to isolate 14-3-3-binding
proteins from lysates of two or three sets of cells exposed to
different agonists and/or inhibitors. Proteins that bind
specifically to the immobilised 14-3-3 s can be released
by competitive elution with a synthetic 14-3-3-binding
phosphopeptide. After digestion of the proteins, the pep-
tides are reacted with formaldehyde and borohydride to
dimethylate every primary amine, with the chemicals for
each preparation labelled with different stable isotopes to
generate a ‘light’, ‘intermediate’ or ‘heavy’ dimethyl moie-
ty. Mass spectrometry is then used to identify the sequence
of the peptides, and to determine the ratio of the light,
intermediate and heavy forms of each peptide. In this way,
proteins whose peptides are more abundant in, for exam-
ple, the 14-3-3-captured sample from insulin-stimulated
than from unstimulated cells or inhibitor-treated cells can
be identified [24,25]. Because the dimethyl labelling step is
carried out after proteins are proteolytically digested, this
method has potential to identify insulin-regulated proteins
isolated from their physiological target tissues. Another
strategy uses a similar principle, except that the differen-
tial isotope label is introduced into proteins by metabolic
incorporation of ‘light’, ‘intermediate’ or ‘heavy’ stable
isotopically labelled amino acids that are fed to cells in
culture (SILAC) [26,27]. Other quantitation methods, such
as differential isobaric tag for relative and absolute quan-
titation (iTRAQ) labelling of protein and peptide samples
and even label-free methods, are also possible, and each
method has its advantages and disadvantages [27,28].
14-3-3 phosphoproteomics data indicate new regulatory
mechanisms for insulin
The first experiments using 14-3-3-phosphoproteomics
technology have identified many proteins that bind to
14-3-3 s in response to signalling pathways that are acti-
vated by insulin [24,26,27]. The insulin-regulated 14-3-3-
binding sites have been verified for fewer proteins. Some of
these proteins have poorly defined functions, including
coiled-coil domain protein 6 (CCDC6), the E3 ubiquitin
ligase zinc-finger, RING-finger 2 (ZNRF2), and the sterile
alpha motif (SAM) and SRC homology 3 (SH3) domain
protein SASH1 [24]. Intriguingly, it was found that a
single-nucleotide polymorphism in the SASH1 gene is
associated with diabetic nephropathy genes in African
Americans in a genome-wide study, so study of this protein
may reveal new disease mechanisms [10]. Other insulin-
regulated 14-3-3-binding proteins provide more immediate
insights into the known actions of the hormone. These
include proteins that regulate insulin-stimulated glucose
uptake into tissues, namely the Rab GTPase-activating
proteins AS160 (TBC1D4) and TBC1D1; the myosin
MYO1C; the cardiac glycolytic activator PFKFB2; the
transcriptional regulator and E3 SUMO-protein ligase
PIAS2 (Miz1); transcription factors FOXO1, FOXO3,
FOXO4 and capicua; ECD3, which is involved in decapping
mRNA as a step in its degradation; cell cycle and apoptotic
Review Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11control proteins including CDKN1B (p27, Kip1), beta-cate-
nin, BAD and BIM; and components of the insulin signal-
ling PI3K–PKB–mTOR pathway itself, namely IRS2
(insulin receptor substrate 2), PRAS40 (AKT1S1) and
rictor [3,17,21,24,26,27,29–40]. Overall, a network of 14-
3-3–phosphoprotein interactions is emerging that is pro-
viding mechanistic insights into how insulin stimulates
glucose assimilation, activates cardiac glycolysis, and reg-
ulates transcription, protein synthesis, feedback control of
insulin signalling, cytoskeletal dynamics and other intra-
cellular events.
It should be emphasised that none of the above-men-
tioned proteins are regulated solely by insulin. Insulin
signalling and other pathways converge on several 14-3-
3-binding sites, and some of these proteins are also modu-
lated by energy and nutrient levels [41]. An intriguing idea
is that 14-3-3 dimers as fuzzy AND logic gates might
integrate insulin signals with other inputs. For example,
there is an interplay between insulin and amino acids in
stimulating phosphorylation of the 14-3-3-binding site(s)
on PRAS40 [42,43]. In addition, 14-3-3 interacts with the
cardiac PFKFB2 via a high-affinity PKB-phosphorylated
site and a second site that can be phosphorylated by both
PKB and AMPK, which is activated when the energy or
ATP status of cells is low, for example during ischaemia
[3,44]. Insulin enhances the ability of cardiomyocytes to
survive ischaemia, and a functional role for 14-3-3 is
indicated by the finding that the PKB-mediated increases
in fructose-2-6-bisphosphate levels and glycolysis are
prevented by a cell-permeable 14-3-3-binding phosphopep-
tide in cells containing cardiac PFKFB2 [3].
Another key physiological process in which insulin sig-
nalling is integrated with other inputs is the uptake of
glucose into muscles [45]. The goal of improving glucose
control in individuals means that the underlying mecha-
nisms are under intense research, and the next section
outlines the contributions of two 14-3-3-binding proteins,
the related Rab GTPase activating proteins (Rab-GAPs)
AS160 (TBC1D4) and TBC1D1. Both proteins are regulat-
ed by multiple phosphorylations [46,47] and details of
relevant kinases and the roles of some sites are still
controversial, a situation that is being resolved with im-
proved reagents for phosphosite identification and quanti-
fication. Readers should therefore note that we do not
attempt to be comprehensive here, but present a personal
14-3-3-centred perspective with a testable hypothesis.
Differential regulation of AS160 and TBC1D1
Insulin promotes glucose uptake into muscles and fat
through GLUT4 glucose transporters [48]. In unstimulated
cells, GLUT4 is localised to internal storage vesicles that
must fuse with the plasma membrane before glucose can
flow into cells. GLUT4 trafficking to the plasma membrane
is stimulated by insulin signalling mainly via the PI3K–
PKB pathway, and impairment of this process is an early
sign of insulin resistance and type 2 diabetes [46,48]. In
skeletal and cardiac muscle, GLUT4 trafficking is also
activated by contraction, which activates protein kinases,
including AMPK, which is activated by lowering ATP
levels [49]. There is considerable interest in understanding
how exercise, as well as drugs that activate AMPK, restoreglucose homeostasis in individuals with insulin resistance
[50].
GLUT4 trafficking requires active GTP-bound Rab pro-
teins. AS160 and the closely related Rab-GAP, TBC1D1,
promote GTP hydrolysis by Rabs. It has been proposed that
these Rab-GAPs are somehow inactivated by phosphoryla-
tion via insulin and AMPK signalling, which allows the
relevant Rabs to be loaded with GTP to facilitate GLUT4
trafficking [51–54]. AS160 and TBC1D1 have similar do-
main architectures, and both proteins have two 14-3-3-
binding sites that are located within clusters of multisite
phosphorylation in a part of the protein that also has so-
called PTB domains (Figure 3). Beyond this superficial
similarity, however, some key regulatory details for
AS160 and TBC1D1 are distinct.
AS160 is named for its discovery as an AKT (PKB)
substrate, and the effects of overexpression of a nonpho-
sphorylatable mutant [AS160(4P)] first implicated this
protein in GLUT4 trafficking [53,55]. Furthermore, a re-
cent genetic analysis identified patients with severe insu-
lin resistance during puberty who carry a premature stop
mutation in one allele of AS160 [56], which underscores the
need to define precisely how AS160 regulates glucose
homeostasis. Insulin stimulates phosphorylation of several
sites of AS160 and induces its binding to 14-3-3 s mainly
through PKB-phosphorylated Thr642, with support from
phospho-Ser341, which can be phosphorylated by p90RSK
and PKB [29,37,53]. A form of AS160 that binds 14-3-3
constitutively, generated by genetic mutation, could over-
ride the inhibitory effect of AS160(4P) on GLUT4 translo-
cation in adipocytes [29,37,53]. In addition, insulin-
stimulated fusion of GLUT4 vesicles with the plasma
membrane was prevented by blocking the AS160–14-3-3
interaction in cell-free assays, which further indicates a
functional role for 14-3-3 in this process [57]. It was ini-
tially proposed that Thr642 on AS160 was a convergence
point for phosphorylation by both PKB and AMPK [58].
However, in vitro and cell culture studies suggest that
whereas AMPK may phosphorylate other residues, AMPK
does not seem to be a physiological Thr642 kinase [29,59].
Therefore, 14-3-3 binds to phospho-Thr642 and phospho-
Ser341 in response to insulin and growth factors, and not
AMPK activators (Figure 3).
In contrast to AS160, AMPK has a clear role in mediat-
ing 14-3-3 binding to the related TBC1D1 [60]. TBC1D1
was originally identified as a candidate gene underlying
severe familial female obesity [61] and its natural deletion
in mice resulted in leanness and protection against diet-
induced obesity [62]. TBC1D1 and AS160 share a similar
substrate preference towards Rabs, at least in vitro [63],
and overexpression of a form of TBC1D1 mutated at three
of its phosphorylation sites interfered with GLUT4 trans-
location in 3T3-L1 adipocytes [64].
In cultured L6 myotubes and intact skeletal muscles,
whereas AS160 is phosphorylated on Ser341 and Thr642
and binds to 14-3-3 s in response to insulin, TBC1D1 is
phosphorylated on Ser237 and binds to 14-3-3 s in response
to acute exercise [65] and pharmacological AMPK activa-
tors [60,66]. Insulin and growth factors also stimulate the
phosphorylation of a second 14-3-3-binding site at Thr596
of TBC1D1, which is similar to Thr642 of AS160; thus,433
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Figure 3. Hypothesis of complementary regulation of glucose homeostasis by AS160 and TBC1D1 in skeletal muscles. Domains, motifs and disease-associated mutations
(the latter in red) are shown in bar diagrams of AS160 and TBC1D1 (see the text for sources). PTB1 and PTB2 are phosphotyrosine interaction domains (by sequence,
although their interaction partners have not been reported); CBD is a calcium-regulated region; and Rab GAP is the Rab GTPase-activating domain. In the hypothesis shown
here, AMPK controls GLUT4 trafficking through Ser237 phosphorylation and consequent docking of 14-3-3 onto the TBC1D1 protein, whereas the insulin–PKB (AKT)
pathway regulates surface translocation of GLUT4 via Thr642 phosphorylation and consequent 14-3-3 binding of the AS160 protein. This hypothesis does not take into
account that both TBC1D1 and AS160 also receive other regulatory inputs via the other phosphorylations that are clustered close to the 14-3-3-binding sites on these
proteins. Phosphorylated residues are indicated by numbers above the bar diagrams, with the 14-3-3-binding sites in yellow. R125W is an obesity-linked mutation of
TBC1D1 [61], and R363W is a diabetes-linked mutation of AS160 [56].
Review Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11TBC1D1 seems to be a dual-input 14-3-3 logic gate
(Figure 3). The functional significance of this molecular
arrangement is not yet clear, however, and, at least in
muscles, phosphorylation of Thr596 alone is insufficient for
14-3-3 binding [60,65].
Complementary roles of AS160 and TBC1D1 for insulin
and AMPK activators
We propose that 14-3-3 binding to AS160 regulates glucose
homeostasis in response to insulin, whereas 14-3-3 binding
to TBC1D1 regulates this process in response to AMPK-
activating stimuli (Figure 3). To test this hypothesis of
complementary roles for AS160–14-3-3 and TBC1D1–14-3-
3 complexes in GLUT4 regulation, mice with knock-in
mutations in the 14-3-3-binding phosphorylation sites in
AS160 and TBC1D1 must be generated. Unlike studies
using ectopic overexpression, introduction of a point mu-
tation of a phospho-Ser/Thr residue to a nonphosphoryla-
table residue using knock-in genetic technology generally
results in expression of mutant proteins at endogenous
levels [67] (provided that mutations do not cause unexpect-
ed outcomes such as destabilisation of the protein), without
exerting dominant-negative effects or competition from
wild-type proteins.
First, a mouse model with Thr649 on AS160 (equivalent
to Thr642 on human AS160) substituted by alanine
was generated to prevent insulin-stimulated binding to
14-3-3 in vivo [67]. The most striking phenotype of the
AS160-Thr649Ala knock-in mice is their altered glucose434homeostasis, including glucose intolerance and reduced
insulin sensitivity. Despite elevated total GLUT4 protein
levels in skeletal muscles and fat tissues of the knock-ins,
GLUT4 is not efficiently localised to the cell surface, which
results in a reduced glucose uptake rate in muscle in re-
sponse to insulin [67]. Together, these findings confirm that
insulin-stimulated Thr649 phosphorylation and 14-3-3
binding to AS160 in muscle has a key role in glucose
homeostasis.
Further experiments are needed to address the com-
plexity of the glucose uptake process, including genetic
tests of the roles of the AMPK and insulin-regulated 14-3-
3-binding sites on TBC1D1. For wider health implications,
we need to know if the knock-in mice display altered
physiological responses to high-fat diets and ageing. Will
the phenotype of TBC1D1 mice provide an insight into the
obesity of individuals with mutations or polymorphisms in
this protein or gene? Would genetic crosses between the
knock-in AS160 and TBC1D1 mice and ‘diabetes loci’
reveal synergism with respect to insulin resistance?
Answers to such questions would help to determine wheth-
er it would be useful to devise drugs that mimic the effects
of insulin and exercise on AS160 and TBC1D1 as means to
improving blood glucose management.
The future: 14-3-3-phosphoproteome barcodes
More general lessons may also be learned from this narrow
focus on AS160 and TBC1D1. Earlier in this review, we
alluded to the possibility of using 14-3-3 capture and
Review Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11phosphoproteomics to identify the commonalities and dif-
ferences in insulin targets in specialised organs of the body.
Another exciting issue would be the potential of developing
these technologies to track which signalling pathways are
activated in cells and tissues under normal conditions and
in response to therapeutic drugs. As exemplified by the
contrast between AS160 and TBC1D1, each protein has its
own signalling signature, meaning its own pattern of
responsiveness to one, two or many signalling pathways.
In turn, this means that insulin, growth factors and other
stimuli, which activate signalling pathways to different
extents, will each induce the phosphorylation and 14-3-3
binding of distinct, but overlapping, subsets of targets. In
other words, each stimulus will have its own ‘barcode’
within the 14-3-3 phosphoproteome in individual cells
and tissues. Definition of the commonalities and differ-
ences in insulin responses in specialised organs and cells of
the body, and any further overlaps between the insulin-
regulated 14-3-3 phosphoproteome and emerging genetic
maps of diabetes and other diseases, will be important
priorities for future metabolic research (Figure 3).
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